Comprehensive characterization of differential glycation in hepatocellular carcinoma using tissue proteomics with stable isotopic labeling
- PMID: 38922433
- DOI: 10.1007/s00216-024-05392-9
Comprehensive characterization of differential glycation in hepatocellular carcinoma using tissue proteomics with stable isotopic labeling
Abstract
Glycation is a non-enzymatic posttranslational modification coming from the reaction between reducing sugars and free amino groups in proteins, where early glycation products (fructosyl-lysine, FL) and advanced glycation end products (AGEs) are formed. The occurrence of glycation and accumulation of AGEs have been closely associated with hepatocellular carcinoma (HCC). Here, we reported the characterization of differential glycation in HCC using tissue proteomics with stable isotopic labeling; early glycation-modified peptides were enriched with boronate affinity chromatography (BAC), and AGEs-modified peptides were fractionated with basic reversed-phase separation. By this integrated approach, 3717 and 1137 early and advanced glycated peptides corresponding to 4007 sites on 1484 proteins were identified with a false discovery rate (FDR) of no more than 1%. One hundred fifty-five sites were modified with both early and advanced end glycation products. Five early and 7 advanced glycated peptides were quantified to be differentially expressed in HCC tissues relative to paired adjacent tissues. Most (8 out of 10) of the proteins corresponding to the differential glycated peptides have previously been reported with dysregulation in HCC. The results together may deepen our knowledge of glycation as well as provide insights for therapeutics.
Keywords: Advanced glycation end products; Differential expression; Early glycation product; Glycation; Hepatocellular carcinoma.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
References
-
- Rabbani N, Thornalley PJ. Protein glycation - biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine. Redox Biol. 2021;42:101920. https://doi.org/10.1016/j.redox.2021.101920 . - DOI - PubMed - PMC
-
- Shahab U, Tabrez S, Khan MS, Akhter F, Khan MS, Saeed M, et al. Immunogenicity of DNA-advanced glycation end product fashioned through glyoxal and arginine in the presence of Fe3+: its potential role in prompt recognition of diabetes mellitus auto-antibodies. Chem Biol Interact. 2014;219:229–40. https://doi.org/10.1016/j.cbi.2014.06.012 . - DOI - PubMed
-
- Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26(2):77–82. https://doi.org/10.2337/diaclin.26.2.77 . - DOI
-
- Nicolls MR. The clinical and biological relationship between type II diabetes mellitus and Alzheimer‘s disease. Curr Alzheimer Res. 2004;1(1):47–54. https://doi.org/10.2174/1567205043480555 . - DOI - PubMed
-
- Munch G, Gerlach M, Sian J, Wong A, Riederer P. Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol. 1998;44(3):S85–8. https://doi.org/10.1002/ana.410440713 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
